00:16 Fri 14 Jun 2019
Shield Therapeutics - Result of AGM
("Shield" or the "Group")
Result of 2019 Annual General Meeting
The following table shows the votes cast on each resolution:
|
VOTES |
% |
VOTES |
% |
VOTES |
% of ISC VOTED |
VOTES |
1 |
91,099,593 |
99.16 |
769,230 |
0.84 |
91,868,823 |
78.46% |
0 |
2 |
86,706,679 |
94.40 |
5,144,503 |
5.60 |
91,851,182 |
78.45% |
17,641 |
3 |
91,079,163 |
99.14 |
789,611 |
0.86 |
91,868,774 |
78.46% |
49 |
4 |
86,767,461 |
94.45 |
5,101,313 |
5.55 |
91,868,774 |
78.46% |
49 |
5 |
91,868,823 |
100.00 |
0 |
0.00 |
91,868,823 |
78.46% |
0 |
6 |
85,998,231 |
93.61 |
5,870,543 |
6.39 |
91,868,774 |
78.46% |
49 |
7 |
91,065,998 |
99.14 |
790,943 |
0.86 |
91,856,941 |
78.45% |
11,882 |
8 |
91,835,228 |
99.97 |
29,777 |
0.03 |
91,865,005 |
78.46% |
3,818 |
9 |
74,183,338 |
80.76 |
17,677,421 |
19.24 |
91,860,759 |
78.45% |
8,064 |
10 |
74,179,520 |
80.76 |
17,677,421 |
19.24 |
91,856,941 |
78.45% |
11,882 |
11 |
17,401,749 |
18.94 |
74,455,192 |
81.06 |
91,856,941 |
78.45% |
11,882 |
12 |
91,856,941 |
100.00 |
0 |
0.00 |
91,856,941 |
78.45% |
11,882 |
The Board reports that resolutions 1 to 9 passed as ordinary resolutions and resolutions 10 and 12 were passed as special resolutions. Special resolution 11 was not passed, however resolutions 9 and 10 were obtained which authorise the Company to allot equity share capital including the right to issue up to 5% of issued share capital disapplying pre-emption rights.
Notes
1. Percentage of shares voted: 78.46% (Number of shares in issue 117,088,657).
2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/investors/corporate-documents/.
3.
- Ends -
For further information please contact:
|
|
|
+44 (0)20 7186 8500 |
|
|
|
|
Nominated Advisor and Broker |
|
|
|
|
+44 (0)20 7418 8900
|
|
|
Joint Broker |
|
finnCap Ltd |
+44 (0)20 7220 0500 |
|
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
|
+44 (0)7980 541 893 / +44 (0)7841 917 679 |
About
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE